Scarica l'app Stockscreener
29.97
0.57%
0.17
Dopo l'orario di chiusura:
30.00
0.03
+0.10%
Precedente Chiudi:
$29.80
Aprire:
$30.02
Volume 24 ore:
519.63K
Relative Volume:
1.04
Capitalizzazione di mercato:
$1.84B
Reddito:
-
Utile/perdita netta:
$-209.84M
Rapporto P/E:
-6.558
EPS:
-4.57
Flusso di cassa netto:
$-6.73M
1 W Prestazione:
+15.22%
1M Prestazione:
+42.65%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$29.05
$30.52
Intervallo di 1 settimana:
$25.76
$30.75
Portata 52W:
$16.50
$30.75
Damora Therapeutics Inc Stock (DMRA) Company Profile
Nome
Damora Therapeutics Inc
Settore
Industria
Telefono
(781) 281-9020
Indirizzo
221 CRESCENT STREET, WALTHAM
Compare DMRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DMRA
Damora Therapeutics Inc
|
29.97 | 1.83B | 0 | -209.84M | -6.73M | -4.57 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-03-25 | Iniziato | Evercore ISI | Outperform |
| 2026-02-17 | Iniziato | UBS | Buy |
| 2026-01-07 | Iniziato | Leerink Partners | Outperform |
| 2025-12-01 | Iniziato | Guggenheim | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-11-23 | Iniziato | BofA Securities | Buy |
| 2020-11-23 | Iniziato | Credit Suisse | Outperform |
| 2020-11-23 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Damora Therapeutics Inc Borsa (DMRA) Ultime notizie
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
Price to sales forward of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Damora awards 453,500 stock options to nine new hires - Stock Titan
RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Damora Therapeutics, Inc.(NasdaqCM:DMRA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2500 Growth Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2000 Index - marketscreener.com
Damora Therapeutics (DMRA) Is Up 6.2% After Broad Russell Index Additions Has The Bull Case Changed? - simplywall.st
Damora Therapeutics, Inc. Actuals & Estimates (NASDAQ:DMRA) - TradingView
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2000 Value Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2000 Growth Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 3000E Growth Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 3000E Value Benchmark - marketscreener.com
Damora Therapeutics Rises as Traders Focus on Near-Term Pipeline Catalysts - Quiver Quantitative
Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat
DMRA Forecast — Price Target — Prediction for 2027 - TradingView
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Chart and Price History 2026 - MarketBeat
Form 144 Damora Therapeutics For: 22 June By Investing.com - Investing.com India
DMRA (NASDAQ: DMRA) Form 144 lists option-based sales to Maxim Group - Stock Titan
Damora Therapeutics (DMRA) Slips 0.89% as Stock Holds Above Key SupportOn Balance Volume - dars.gov.et
Damora Therapeutics, Inc. Common Stock (DMRA) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Damora Therapeutics Announces Results of 2026 Annual Meeting - TipRanks
DMRA: All proposals passed, including director elections and auditor ratification, with strong shareholder support - TradingView
Damora Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Guggenheim Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
DMRA Q1 2026 Earnings: EPS Misses Estimates as Clinical Costs WeighEBITDA Margin Trends - newsline.com
DMRA Reiterates by Wedbush -- Price Target Maintained at $35 - GuruFocus
DMRA Initiated Coverage by HC Wainwright & Co. -- Price Target S - GuruFocus
Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026 - MarketBeat
Damora Therapeutics Inc Azioni (DMRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Damora Therapeutics Inc Azioni (DMRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bruno Julianne | Director |
Feb 09 '26 |
Option Exercise |
0.00 |
129,000 |
0 |
137,032 |
| Fairmount Funds Management LLC | Director |
Feb 09 '26 |
Option Exercise |
0.00 |
8,713,000 |
0 |
5,809,000 |
| Schambye Hans T. | Chief Executive Officer |
Jan 02 '26 |
Sale |
21.38 |
700 |
14,966 |
4,682 |
| Winslow Garrett | General Counsel |
Jan 02 '26 |
Sale |
21.38 |
255 |
5,452 |
1,854 |
| Firmani Lori | Chief Financial Officer |
Jan 02 '26 |
Sale |
21.41 |
135 |
2,890 |
931 |
1.18%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):